Lixin Lang

Title: Lixin Lang: Innovator in Autoimmune Disease Treatment

Introduction

Lixin Lang is a prominent inventor based in Princeton, NJ (US), known for his significant contributions to the field of autoimmune disease treatment. His innovative work has led to the development of methods that utilize domain antibodies to address various autoimmune conditions.

Latest Patents

Lixin Lang holds a patent titled "Methods of treating autoimmune disease using a domain antibody directed against CD40L." This patent focuses on treating autoimmune diseases such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis. The invention involves antibody polypeptides that specifically bind to human CD40L without activating platelets. The methods may include at least one administration cycle with a dose of the antibody polypeptide administered intravenously, ranging from about 75 mg to about 1500 mg. This innovative approach aims to normalize platelet counts in human patients.

Career Highlights

Lixin Lang is associated with Bristol-Myers Squibb Company, where he continues to advance research in the treatment of autoimmune diseases. His work has garnered attention for its potential to improve patient outcomes and enhance therapeutic options.

Collaborations

Lixin collaborates with esteemed colleagues, including Marek Honczarenko and Vaishali Shah, contributing to a dynamic research environment focused on innovative solutions for complex medical challenges.

Conclusion

Lixin Lang's contributions to the field of autoimmune disease treatment exemplify the impact of innovative research and development. His patent and ongoing work at Bristol-Myers Squibb Company highlight the importance of advancing medical science to improve patient care.